GLP-1 RAs & Incretin Based Therapies - Competitive landscape, 2026

DelveInsight's, "GLP-1 RAs & Incretin Based Therapies - Competitive landscape, 2026," report provides comprehensive insights about 180+ companies and 200+ drugs in GLP-1 RAs & Incretin Based Therapies Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

GLP-1 RAs & Incretin Based Therapies: Understanding

GLP-1 RAs & Incretin Based Therapies: Overview

GIP and GLP-1 are the two primary incretin hormones that regulate glucose homeostasis. GIP, secreted mainly by K cells in the duodenum and jejunum, enhances glucose-dependent insulin secretion, while GLP-1, produced predominantly by L cells in the ileum and colon, exerts potent insulinotropic effects. Both hormones play essential roles in maintaining glucose control and are highly conserved across mammalian species.

GIP and GLP-1 are complementary incretin hormones that regulate glucose and lipid metabolism through overlapping yet distinct mechanisms. GIP enhances glucose-dependent insulin secretion, glucagon release during hypoglycemia, and adipose lipid storage, whereas GLP-1 promotes insulin secretion, suppresses glucagon during hyperglycemia, delays gastric emptying, and increases satiety. Both act through class B GPCRs and cAMP-mediated signaling but have short half-lives due to rapid DPP-4 degradation. Their complementary effects support the therapeutic use of GLP-1 receptor agonists and dual GIP/GLP-1 agonists such as semaglutide and tirzepatide.

GIP and GLP-1 are important therapeutic targets for T2DM and obesity, with GLP-1 having more established clinical benefits. While GIP activity is impaired in T2DM, its activation may enhance glucose control when combined with GLP-1 signaling. GLP-1 improves glycemic control and promotes weight loss by enhancing satiety, reducing food intake, and influencing energy metabolism. These complementary effects have driven the development of dual- and multifunctional incretin therapies, including the GIP/GLP-1 receptor agonist tirzepatide and the GIPR antagonist/GLP-1R agonist maridebart cafraglutide, which may offer greater metabolic benefits than single-incretin therapies.

Native GIP and GLP-1 have short half-lives, prompting the development of longer-acting incretin analogues with improved stability and pharmacokinetics. GLP-1 agonists such as exenatide, liraglutide, dulaglutide, and semaglutide incorporate structural modifications to resist DPP-4 degradation and prolong circulation, enabling daily, weekly, and oral dosing. Building on these advances, dual GIP/GLP-1 agonists such as tirzepatide combine complementary incretin pathways to enhance therapeutic efficacy. These innovations have expanded incretin therapies from glycemic control to weight management and broader cardiometabolic benefits.

T2DM management has evolved beyond glycemic control toward integrated management of obesity and cardiometabolic risk. GLP-1RAs and tirzepatide provide substantial HbA1c reductions, with tirzepatide showing particularly strong efficacy, while long-acting agents generally offer better overall glycemic control and lower hypoglycemia risk than insulin. These therapies also promote clinically meaningful weight loss, with tirzepatide generally producing the greatest reductions. Several GLP-1RAs, including liraglutide, semaglutide, albiglutide, and dulaglutide, have demonstrated cardiovascular benefits, including reduced MACE, whereas tirzepatide's cardiovascular effects remain under evaluation. Overall, incretin-based therapies now offer broader benefits across glycemic control, weight management, cardiovascular risk, and potentially renal protection.

Report Highlights:

• In August 2026, Neurocrine Biosciences, Inc. announced the initiation of a Phase I first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity.
• In June 2026, Hansoh Pharmaceutical Group Company Limited announced the New Drug Application (NDA) for the Group's innovative drug Olatorepatide Injection has been accepted by the National Medical Products Administration (NMPA) of China for chronic weight management in obese and overweight adult patients.
• In May 2026, Eli Lilly and Company, the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), announced positive topline results from TRIUMPH-1, a Phase III clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes. At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and 12 mg) met the primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss.
• In April 2026, MetaVia Inc. announced that the first patient has been dosed in Part 3 of its Phase I clinical trial evaluating DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. Part 3 of the Phase I program consists of two 16-week titration cohorts designed to evaluate one-step and two-step dose-escalation strategies to safely achieve higher target doses and further optimize tolerability.
• In February 2026, Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new-generation cAMP-biased GLP-1 receptor agonist. Under the agreement, Pfizer will obtain exclusive commercialization rights for the product in Mainland China, marking an important first step to advance Pfizer's global strategy in the metabolic field in China. Sciwind Biosciences will remain the Marketing Authorization Holder and will be responsible for research and development, registration, manufacturing, and supply of the product. Under the terms of the agreement, Sciwind Biosciences is eligible to receive up to USD 495M in upfront, regulatory and sales milestone payments.
• In February 2026, Pfizer Inc. announced positive topline results from the Phase IIb VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF'3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes.
• In January 2026, Roche announced positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to 24 mg) resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (efficacy estimand) without reaching a weight loss plateau at 48 weeks. A clear dose-response relationship on the weight loss was observed. For the treatment-regimen estimand, the placebo-adjusted weight loss achieved with CT-388 was 18.3% (p-value < 0.001). At week 48 for the 24 mg dose, 95.7% of CT-388 treated participants achieved a weight loss of >=5%, 87% achieved >=10%, 47.8% achieved >=20%, and 26.1% achieved >=30%. 73% of participants who were pre-diabetic at baseline and treated with CT-388 at 24 mg achieved normal blood glucose levels at week 48 compared to 7.5% in the placebo group. The treatment was well-tolerated, with the majority of gastrointestinal-related adverse events being mild-to-moderate, generally consistent with the incretin class of medicines. In addition, the treatment discontinuation rate due to adverse events was low (5.9% in CT-388 arms; 1.3% in placebo arm).
• In January 2026, AstraZeneca strengthens its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes. Under this agreement, the companies will initially progress four programmes, which utilise CSPC's advanced AI-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology. AstraZeneca will receive exclusive global rights outside of China to CSPC's once-monthly injectable weight management portfolio, comprising one clinical-ready asset, SYH2082, a long-acting GLP1R/GIPR agonist progressing into Phase I and three preclinical programmes with differing mechanisms designed to provide extended therapeutic benefits for people living with obesity and weight-related conditions.
• In December 2025, Pfizer Inc. announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600196.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase I development for chronic weight management.
• In June 2025, Regeneron Pharmaceuticals, Inc. announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited to acquire exclusive clinical development and commercial rights outside of the Chinese Mainland, Hong Kong and Macau for a dual GLP-1/GIP receptor agonist currently in Phase III testing. This novel therapeutic candidate (HS-20094), studied in over 1,000 patients and administered as a weekly subcutaneous injection, has demonstrated promising efficacy and safety clinical data, suggesting a potentially similar profile to the only FDA-approved GLP-1/GIP receptor agonist. A Phase III trial in obesity in China and Phase IIb study in diabetes are ongoing.
• In May 2025, Septerna, Inc. and Novo Nordisk announced an exclusive global collaboration and license agreement to discover, develop and commercialise oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases. The companies will initially commence four development programmes for potential small molecule therapies directed to one or more select G protein-coupled receptor (GPCR) targets, including the GLP-1, GIP and glucagon receptors.

GLP-1 RAs & Incretin Based Therapies: Company and Product Profiles (Marketed Therapies)

1. Company Overview: Eli Lily and Company

Eli Lilly and Company is a global pharmaceutical company focused on transforming scientific discoveries into innovative medicines that improve health and quality of life. With nearly 150 years of research and development experience, Lilly leverages biotechnology, chemistry, and genetic medicine to address major healthcare challenges, including diabetes, obesity, Alzheimer's disease, immune disorders, and difficult-to-treat cancers. The company also emphasizes diverse clinical trials and efforts to improve the accessibility and affordability of its medicines worldwide.

Product Description: Mounjaro

Mounjaro(R) (tirzepatide) is a once-weekly, injectable dual GIP/GLP-1 receptor agonist developed by Eli Lilly and Company for the treatment of type 2 diabetes (T2D). It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety, resulting in improved glycemic control and weight reduction. Tirzepatide has demonstrated substantial reductions in HbA1c and body weight compared with several established diabetes therapies. Its dual incretin mechanism represents an advancement over selective GLP-1 receptor agonists by simultaneously activating GIP and GLP-1 pathways. In May 2022, the U.S. Food and Drug Administration (FDA) approved Mounjaro(TM) (tirzepatide) injection, Eli Lilly and Company's new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

2. Company Overview: Novo Nordisk

Novo Nordisk is a leading global healthcare company with more than a century of experience developing innovative medicines for diabetes and other serious chronic diseases, including obesity and rare blood and endocrine disorders. The company focuses on long-term, sustainable growth through scientific innovation and financially, socially, and environmentally responsible business practices. In the US, Novo Nordisk has operated for approximately 40 years, with its headquarters in New Jersey and around 10,000 employees across more than 10 manufacturing, R&D, and corporate locations in seven states and Washington, DC.

Product Description: Ozempic

Ozempic(R) (semaglutide) is a prescription medicine used alongside diet and exercise to improve blood glucose control in adults with type 2 diabetes. Ozempic injection is additionally indicated to reduce the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with T2D and established heart disease, and to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with T2D and chronic kidney disease. Ozempic tablets are also indicated for cardiovascular risk reduction in adults with T2D who are at high risk of major cardiovascular events. The safety and efficacy of Ozempic injection and tablets in children have not been established.

GLP-1 RAs & Incretin Based Therapies: Company and Product Profiles (Pipeline Therapies)

1. Company Overview: Regeneron / Hansoh Pharma

Regeneron is a leading biotechnology company focused on discovering, developing, and commercializing transformative medicines for serious diseases. Founded and led by physician-scientists, the company leverages its in-house scientific expertise and proprietary technologies, including VelociSuite(R) and the Regeneron Genetics Center(R), to accelerate drug discovery and development. Its diverse pipeline addresses major therapeutic areas such as eye diseases, allergic and inflammatory disorders, cancer, cardiovascular and metabolic diseases, neurological and hematologic conditions, infectious diseases, and rare disorders, while its advanced antibody and genetic medicine platforms support the identification of novel therapeutic targets and innovative treatment approaches.

Hansoh Pharma is a leading innovation-driven pharmaceutical company in China, focused on major therapeutic areas including oncology, anti-infectives, central nervous system (CNS) disorders, metabolism, and immunology. Guided by its mission of "continuous innovation for better life," the company has launched seven innovative medicines in China, with innovative and collaborative products contributing more than 80% of revenue and supporting a broad development pipeline. Hansoh Pharma consistently ranks among the top 100 global pharmaceutical companies and top three pharmaceutical R&D enterprises in China, and is recognized as a National Key High-Tech Enterprise and National Technology Innovation Demonstration Enterprise. The company has been listed on the Hong Kong Stock Exchange since June 2019.

Product Description: Olatorepatide

Olatorepatide is a proprietary dual GLP-1/GIP receptor agonist discovered and developed in-house by Hansoh Pharma. By selectively activating GLP-1 and GIP receptors, the drug modulates metabolic pathways governing appetite suppression, glucose homeostasis, and energy balance to deliver glycemic control and weight reduction benefits. It is administered once weekly via subcutaneous injection. Currently, the drug is in Phase III stage of its development for the treatment of indications for cardio metabolic health. The New Drug Application was accepted by NMPA for for chronic weight management in adults with obesity or overweight. Currently, the therapy is in Registration stage of its development for the treatment of indications for cardio metabolic health.

2. Company Overview: Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company focused on transforming scientific discoveries into innovative medicines that improve health and quality of life. With nearly 150 years of research and development experience, Lilly leverages biotechnology, chemistry, and genetic medicine to address major healthcare challenges, including diabetes, obesity, Alzheimer's disease, immune disorders, and difficult-to-treat cancers. The company also emphasizes diverse clinical trials and efforts to improve the accessibility and affordability of its medicines worldwide.

Product Description: Retatrutide

Retatrutide is an investigational once-weekly triple agonist targeting the GIP, GLP-1, and glucagon receptors. Lilly is evaluating its efficacy and safety across multiple Phase III trials in obesity and overweight-related conditions, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease (MASLD). Retatrutide remains investigational and is currently available only to participants enrolled in Lilly-sponsored clinical trials. Currently, the drug is in Phase III stage of its development for the treatment of indications for cardio metabolic health.

3. Company Overview: Pfizer

Pfizer is a global biopharmaceutical company that leverages science and worldwide resources to develop innovative medicines and vaccines that extend and improve patients' lives. The company focuses on maintaining high standards of quality, safety, and value across the discovery, development, and manufacturing of healthcare products, while advancing treatments and preventive solutions for serious diseases. With operations across developed and emerging markets, Pfizer collaborates with healthcare providers, governments, and communities to expand access to reliable and affordable healthcare and has pursued this mission for more than 175 years.

Product Description: PF-08653944

PF-08653944 is an ultra-long-acting, fully biased GLP-1 receptor agonist being investigated as a next-generation incretin-based therapy. The candidate is being developed for once-weekly and potentially once-monthly administration, with the aim of providing sustained GLP-1 receptor activation and improving dosing convenience. In addition to monotherapy, PF-08653944 is being evaluated in combination with other metabolic peptides, including the amylin analogue PF-08653945 (PF'3945; MET-233i) and the GIP receptor agonist PF-08654696 (MET-034i), supporting its potential application in combination-based approaches for metabolic disorders such as obesity and type 2 diabetes. Currently, the drug is in Phase III stage of its development for the treatment of obesity.

4. Company Overview: Roche

Founded in 1896 in Basel, Switzerland, Roche has evolved from an early manufacturer of branded medicines into a global leader in biotechnology and in-vitro diagnostics, focused on developing innovative medicines and diagnostic solutions that improve and save lives. The company is a pioneer in personalized healthcare, integrating pharmaceutical and diagnostic capabilities with real-world clinical data to advance patient-centered care. Sustainability has remained an integral part of Roche's operations for more than 125 years, with the company targeting net-zero emissions by 2045 through initiatives such as the Science Based Targets initiative and Sustainable Markets Initiative. In the United States, Genentech operates as a wholly owned member of the Roche Group, while Roche is the majority shareholder of Chugai Pharmaceutical in Japan.

Product Description: CT-388

CT-388 is an investigational once-weekly subcutaneous dual GLP-1/GIP receptor agonist being developed for obesity, type 2 diabetes, and related metabolic comorbidities. It is designed to reduce appetite and improve glycemic control through potent activation of both GLP-1 and GIP receptors while minimizing B-arrestin recruitment, thereby limiting receptor internalization and desensitization. This biased signaling profile is intended to support prolonged receptor activity and sustained therapeutic effects. Currently, the drug is in Phase III stage of its development for the treatment of obesity and type 2 diabetes.

5. Company Overview: vTv Therapeutics

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative oral, small-molecule therapies for diseases with significant unmet medical needs, particularly in the areas of metabolic, inflammatory, and chronic disorders. The company leverages its proprietary drug-discovery capabilities and expertise in small-molecule biology to develop differentiated treatment approaches designed to improve efficacy, safety, convenience, and patient outcomes. Its research activities span multiple therapeutic pathways, with a broader focus on advancing novel medicines from early discovery through clinical development.

Product Description: TTP273

TTP273 is an investigational oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed for the treatment of type 2 diabetes mellitus (T2DM). In preclinical and clinical studies, TTP273 has demonstrated the ability to reduce postprandial glucose excursions following oral glucose or mixed-meal tolerance tests. GLP-1 is a naturally occurring hormone that activates the GLP-1 receptor and plays an important role in metabolic regulation, with effects including improved glycemic control, reduced inflammation, and potential cardiovascular and neuroprotective benefits. GLP-1 receptor agonists are well-established therapies for lowering HbA1c, supporting weight reduction, and reducing cardiovascular risk in appropriate patient populations. Currently, the drug is in Phase II stage of its development for the treatment of diabetes.

6. Company Overview: Neurocrine Biosciences

Neurocrine Biosciences is a leading biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, psychiatric, endocrine, and immunological disorders with significant unmet medical needs. Its portfolio includes FDA-approved therapies for tardive dyskinesia, Huntington's disease-associated chorea, congenital adrenal hyperplasia, hyperphagia associated with Prader-Willi syndrome, endometriosis, and uterine fibroids, alongside a robust pipeline of mid- to late-stage clinical programs. With more than three decades of expertise in neuroscience and brain-body interactions, Neurocrine continues to advance therapies aimed at reducing the burden of complex and debilitating diseases.

Product Description: NBIP-'1968

NBIP-'1968 is an investigational long-acting, once-weekly triple agonist targeting the GLP-1, GIP, and glucagon receptors to modulate pathways involved in appetite, energy balance, and glycemic control. It is designed with balanced glucagon receptor activity to maximize potential metabolic benefits while maintaining tolerability. Neurocrine is developing NBIP-'1968 within its broader obesity portfolio alongside NBIP-'2118, an investigational corticotropin-releasing factor type 2 receptor agonist currently in Phase I development, with NBIP-'1968 intended for potential use in a fixed-dose combination with NBIP-'2118.

7. Company Overview: MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for cardiometabolic diseases, particularly obesity and metabolic dysfunction-associated steatohepatitis (MASH). Its lead obesity candidate, DA-1726, is a once-weekly GLP-1/glucagon receptor (GLP-1R/GCGR) dual agonist designed to reduce appetite through GLP-1R activation while increasing energy expenditure through glucagon receptor activation. The company is also developing vanoglipel (DA-1241), an oral GPR119 agonist being investigated for MASH and type 2 diabetes. As of 2026, DA-1726 is in Phase I development, with higher-dose studies evaluating dose titration, efficacy, and tolerability.

Product Description: DA-1726

DA-1726 is a novel oxyntomodulin (OXM) analogue and dual GLP-1/glucagon receptor agonist being developed as a once-weekly subcutaneous therapy for obesity and metabolic dysfunction-associated steatohepatitis (MASH). By activating GLP-1 and glucagon receptors, DA-1726 is designed to promote weight loss through appetite suppression and increased energy expenditure. Preclinical studies demonstrated greater weight loss than semaglutide and comparable weight reduction to tirzepatide and survodutide despite higher food intake, while also showing potential benefits in lean-mass preservation and lipid reduction. In a Phase I multiple-ascending-dose study, the 32 mg dose demonstrated promising effects on body weight, glycemic control, and waist circumference, supporting its potential as a next-generation metabolic therapy.

8. Company Overview: Sciwind Biosciences

Sciwind Biosciences is a near-commercial-stage biopharmaceutical company focused on addressing unmet needs in weight management and metabolic diseases. Its pipeline is led by ecnoglutide (XW003) and is supported by proprietary technology platforms for biased agonist discovery, long-acting peptide delivery, and oral peptide delivery. Leveraging these platforms, Sciwind is developing a broad portfolio of injectable and oral therapies targeting GLP-1 and complementary metabolic pathways, with the goal of providing effective and durable treatment options for patients with metabolic disorders.

Product Description: XW014

XW014 is a Phase I oral small-molecule, cAMP-biased GLP-1 receptor agonist being developed as a potentially convenient and scalable alternative to peptide-based therapies. Designed for once-daily dosing, it aims to provide stable pharmacokinetics and a favorable safety profile while offering manufacturing and formulation advantages. Its small-molecule nature may enable greater production scalability, cost efficiency, and flexibility for combination with other oral therapies, potentially supporting synergistic treatment approaches.

GLP-1 RAs & Incretin Based Therapies Analytical Perspective by DelveInsight

• In-depth Commercial Assessment: GLP-1 RAs & Incretin Based Therapies Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

• GLP-1 RAs & Incretin Based Therapies Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

GLP-1 RAs & Incretin Based Therapies Report Assessment

• Company Analysis
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing GLP-1 RAs & Incretin Based Therapies drugs?
• How many GLP-1 RAs & Incretin Based Therapies drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of GLP-1 RAs & Incretin Based Therapies?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the GLP-1 RAs & Incretin Based Therapies therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for GLP-1 RAs & Incretin Based Therapies and their status?
• What are the key designations that have been granted to the emerging and approved drugs?

Key Players

• Eli Lily and Company
• Novo Nordisk
• Regeneron
• Hansoh Pharma
• Pfizer
• Roche
• vTv Therapeutics
• Neurocrine Biosciences
• MetaVia
• Sciwind Biosciences
• CSPC Pharma
• Jiangsu Hengrui Pharmaceuticals
• Kailera Therapeutics
• Viking Therapeutics
• Structure Therapeutics
• D and D Pharmatech
• SCOHIA Pharma Inc.
• Vivani Medical
• Biolexis Therapeutics
• Adocia
• Regor Therapeutics
• RenaissThera
• Immunoforge
• Corxel Pharmaceuticals

Key Products

• Mounjaro
• Mazdutide
• Retatrutide
• Ozempic
• Olatorepatide
• PF-08653944
• CT-388
• TTP273
• NBIP-'1968
• DA-1726
• XW014
• TG103
• HRS9531
• VK 2735
• Aleniglipron
• MET-875
• MET-GGG
• SCO-094
• NPM-115
• Research Program: Next-generation incretins
• BLX-7006
• BLX-Aging Combo
• AdoXLongTM Sema
• AdOral(R) Sema
• RGT-075
• RT-1000
• RT-2000
• RT-4000
• Froniglutide
• CX11